CLEVER CULTURE SYSTEMS LIMITED (ASX: CC5)
Health care · News and insights
CC5: $0.016 +14.29% · MC: $36M
Latest CC5 announcements
Announcement Insights
Clever Culture Systems Reaffirms FY27 Sales Outlook As Smaller APAS Model Advances
Clever Culture Systems has completed six of the eight APAS instrument sales and new evaluations it expects in the first half of FY27, matching its full-year FY26 pharmaceutical placements; two more are expected by year-end, including an order from a new top-20 pharmaceutical company. The company secured a $2.6 million funding package to develop APAS Revolution for smaller facilities, with customer evaluations targeted for 2027 and launch expected in the first half of 2028.
Updated 17 Nov 2026, 11:44 AM Sydney time
Sources
Chair's Address to ShareholdersAGM Managing Director's PresentationApplication for quotation of securities - CC5Notification regarding unquoted securities - CC5Funding Raised for Development of a New Benchtop InstrumentProposed issue of securities - CC5Quarterly Activities/Appendix 4C Cash Flow ReportTrading HaltChange of Registry Address NotificationAdvancing Sales Pipeline Underpins Growth MomentumComments
2026-11-17 · Health care
CC5: $0.016 +14.29% · MC: $36M
Clever Culture Systems says first-half FY27 sales and new evaluations are expected to reach eight APAS instruments, matching its full-year FY26 pharmaceutical placements; six are completed, with two more expected by year-end, including an order from a new top-20 pharmaceutical company. The company also reiterated plans for APAS Revolution, targeting a market it estimates is around 50% larger, with customer evaluations expected in 2027 and launch in the first half of 2028.
Updated 2026-11-17 11:39
Sources
AGM Managing Director's PresentationChair's Address to ShareholdersComments
2026-11-10 · Health care
CC5: $0.015 -11.76% · MC: $36M
Clever Culture Systems issued new shares and options under the funding package announced last week to support development of its smaller APAS system. The share issue increases its quoted ordinary shares, while the options are unquoted and 28.8 million further options under the package remain to be issued.
Updated 2026-11-10 10:35
Sources
Application for quotation of securities - CC5Notification regarding unquoted securities - CC5Comments
2026-11-03 · Health care
CC5: $0.016 -15.79% · MC: $36M
Clever Culture Systems has secured commitments for a $2.6 million funding package—comprising a targeted share placement and an unsecured loan—to develop APAS Revolution, a smaller system aimed at pharmaceutical facilities not served by its existing product. The company estimates the product could expand APAS’s addressable market by approximately 50%, from $2.8 billion to $4.3 billion, while the proposed launch is expected in the first half of 2028. This follows last week’s update that three APAS Independence systems were sold and invoiced in the first quarter of FY27, with eight sales and new evaluations expected in the first half.
Updated 2026-11-03 10:22
Sources
Funding Raised for Development of a New Benchtop InstrumentProposed issue of securities - CC5Comments
2026-10-30 · Health care
CC5: $0.019 +0.00% · MC: $36M
Clever Culture Systems reported three completed and invoiced APAS sales in Q1 FY27, up from one in the same quarter last year, and expects first-half sales and new evaluations to reach eight units, matching full-year FY26 sales to pharmaceutical customers. Separately, it requested a trading halt while completing a material capital raise intended to fund development of a smaller desktop APAS model for lower-volume sterile drug manufacturing facilities.
Updated 2026-10-30 09:12
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportTrading HaltComments
2026-10-29 · Health care
CC5: $0.019 +0.00% · MC: $36M
Clever Culture Systems says its share registry’s address changes from 30 October, with telephone numbers unchanged. Shareholders and others must send documents to the new address from that date.
Updated 2026-10-29 15:33
Sources
Change of Registry Address NotificationComments
2026-10-28 · Health care
CC5: $0.019 +2.70% · MC: $36M
Clever Culture Systems says three APAS Independence sales were completed and fully invoiced in the first quarter of FY27, while it expects first-half sales and new evaluations to reach eight units, matching the full-year FY26 total sold to pharmaceutical customers. Two existing global pharmaceutical customers are expected to progress to purchases, and a new top-20 pharmaceutical company is expected to begin a paid evaluation; these opportunities remain subject to conversion.
Updated 2026-10-28 08:37
Sources
Advancing Sales Pipeline Underpins Growth MomentumComments
Comments